BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36945886)

  • 1. CDK4/6 inhibitors in metastatic breast cancer, a comparison of toxicity and efficacy across agents in a real-world dataset.
    Buller W; Pallan L; Chu T; Khoja L
    J Oncol Pharm Pract; 2023 Dec; 29(8):1825-1835. PubMed ID: 36945886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world incidence and management of adverse events in patients with HR+, HER2- metastatic breast cancer receiving CDK4 and 6 inhibitors in a United States community setting.
    Price GL; Sudharshan L; Ryan P; Rajkumar J; Sheffield KM; Nash Smyth E; Morato Guimaraes C; Rybowski S; Cuyun Carter G; Gathirua-Mwangi WG; Huang YJ
    Curr Med Res Opin; 2022 Aug; 38(8):1319-1331. PubMed ID: 35535675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.
    Eggersmann TK; Degenhardt T; Gluz O; Wuerstlein R; Harbeck N
    BioDrugs; 2019 Apr; 33(2):125-135. PubMed ID: 30847853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of healthcare resource utilization and costs of patients with HR+/HER2- advanced breast cancer treated with ribociclib versus other CDK4/6 inhibitors.
    Burne R; Balu S; Guérin A; Bungay R; Sin R; Paul ML
    J Med Econ; 2021; 24(1):806-815. PubMed ID: 34098827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis.
    Onesti CE; Jerusalem G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):283-298. PubMed ID: 33233970
    [No Abstract]   [Full Text] [Related]  

  • 10. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
    Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
    Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer.
    Cejuela M; Gil-Torralvo A; Castilla MÁ; Domínguez-Cejudo MÁ; Falcón A; Benavent M; Molina-Pinelo S; Ruiz-Borrego M; Salvador Bofill J
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Gene Panel Associated With Abemaciclib Utility in
    Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
    JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Cyclin-Dependent Kinase 4/6 in Metastatic Breast Cancer: Real-World Data From a Tertiary Care Institute in Eastern India.
    Das Majumdar SK; Barik SK; Pattanaik A; Das DK; Parida DK
    Cureus; 2024 Jan; 16(1):e52172. PubMed ID: 38344632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Laderian B; Fojo T
    Semin Oncol; 2017 Dec; 44(6):395-403. PubMed ID: 29935901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data.
    Martin JM; Handorf EA; Montero AJ; Goldstein LJ
    Oncologist; 2022 Jun; 27(6):441-446. PubMed ID: 35552450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDK4-6 inhibitors in breast cancer: current status and future development.
    Choo JR; Lee SC
    Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2- Metastatic Breast Cancer in Postmenopausal Women in the USA.
    Masurkar PP; Damgacioglu H; Deshmukh AA; Trivedi MV
    Pharmacoeconomics; 2023 Jun; 41(6):709-718. PubMed ID: 36920662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer.
    Samuel Eziokwu A; Varella L; Lynn Kruse M; Jia X; Moore HCF; Thomas Budd G; Abraham J; Montero AJ
    Clin Breast Cancer; 2021 Jun; 21(3):205-209. PubMed ID: 33189562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial disparities in neutrophil counts among patients with metastatic breast cancer during treatment with CDK4/6 inhibitors.
    Schreier A; Munoz-Arcos L; Alvarez A; Sparano JA; Anampa JD
    Breast Cancer Res Treat; 2022 Jul; 194(2):337-351. PubMed ID: 35633421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.